MAIA Biotechnology, Inc. presented the efficacy of telomere targeting at a conference in Romania.
The company has started enrollment for a Phase 2 clinical trial in Romania for ateganosine as a treatment for advanced non-small cell lung cancer patients.
CEO Vlad Vitoc emphasized the significance of bringing the Phase 2 expansion trial to Romania.
Telomere Targeting Efficacy Presentation
CEO Vlad Vitoc presented the Phase 2 expansion trial of ateganosine in Romania, showing promising response rates for NSCLC patients.
Expansion to Romania
Enrollment has started in Romania for the THIO-101 Phase 2 clinical trial evaluating ateganosine in NSCLC patients.
Accelerated Approval Strategy
MAIA aims to accelerate patient access to the telomere-targeting therapy and pursue accelerated approval in the U.S.
- Romania, with high incidence rates of NSCLC, is a crucial location for the Phase 2 trial expansion.
- Ateganosine offers a novel treatment approach to overcome immune checkpoint resistance in late-stage NSCLC patients.
The expansion of the THIO-101 Phase 2 trial to Romania signifies a strategic move for MAIA Biotechnology in advancing cancer treatment innovations.